Affimed jumps after Q3 beat, robust growth in top-line of 402%

• Affimed (AFMD +10.3%) Q3 results:
• Revenue of €10.6M (+402.4% Y/Y).
• Operating Loss: (€2.9M) (+76.6%); Net Loss: (€6.0M) (+44.9%); Loss Per Share: (€0.07) (+58.8%).
• Quick Assets: €97.3M, with anticipated cash runway into 1H of 2023.
• Upcoming milestones: AFM13 pTCL REDIRECT monotherapy study's interim analysis expected during 1H of 2021.
• The initiation of the Phase 1 study of drug  RO7297089 in patients with relapsed or refractory multiple Myeloma with Genentech triggered a milestone payment recognized in the 3Q.
• https://seekingalpha.com/news/3634396-affimed-jumped-10-after-q3-beat-robust-growth-in-top-line-of-402